# enGene Therapeutics Inc.: Form 8-K, filed Nov 14, 2025

- Company: [enGene Therapeutics Inc.](/companies/engn.md) (CIK 1980845)
- Form: 8-K
- Filed: 2025-11-14
- Accepted by EDGAR: Nov 14, 2025, 16:39 ET
- Period: 2025-11-12
- Accession: 0001193125-25-283182
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1980845/000119312525283182/d876714d8k.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1980845/000119312525283182/

## Items reported

- Item 1.01: Entry into a material agreement
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1980845/000119312525283182/d876714d8k.htm

Filed Nov 14, 2025.
Source: SEC EDGAR, the filing index for accession 0001193125-25-283182. Last ingested by Listed: Oct 24, 2026, 15:16 ET. No prices; not investment advice.